Advertisement

In Silico Pharmacology

, 6:10 | Cite as

Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study

  • Mokhtar Nosrati
  • Zahra Shakeran
  • Zainab Shakeran
Original Research
  • 28 Downloads

Abstract

Hepatitis B virus (HBV) infects more than 400 million humans Worldwide. Currently, development of new anti-HBV agents is focused on inhibiting of HBV DNA polymerase activity. The natural components of medicinal plant have a broad spectrum of biological activities with therapeutic properties which can be exploited in various steps of drug discovery. Currently, in silico analyses have been introduced as alternative or supplements methods for drug discovery. This study was planned to in silico screening novel HBV DNA polymerase inhibitor(s) from R. palmatum, R. coreanus and S. officinalis. For this purpose, a set of dominant phytochemicals from mentioned plants were retrieved from PubChem database and primary screening was performed with molecular docking method using iGemdock 2.1 software. SwissADME and MedChem Designer 3.0 were used to calculate the drug-likeness parameters of the ligands. Furthermore, the genotoxicity of the studied ligands was predicted using Toxtree 2.6.6 software. Final analysis of screened compounds was done using Autodock 4 software. Result confirmed that Frangulosid and Lindleyin acid have most and least efficacy in HBV DNA polymerase inhibition with the inhibition constant of 2.97 and 53.83 µM, respectively. Results also showed that, the amino acids, involved in interaction, were different for each compound. In this regards, results revealed that the main amino acids residues of the receptor, involved in interaction with Quercetin-3-glucuronide, Frangulosid and Lindleyin separately, located in 420–424, 606–615 and 512–542 spectra, respectively. In conclusion, Frangulosid can be considered as a good candidate for more investigation of its anti-HBV activity.

Keywords

Hepatitis B virus Medical plant In silico analysis Molecular docking 

Notes

Acknowledgements

The authors would like to acknowledge the University of Isfahan for the financial support of this study.

Compliance with ethical standards

Conflict of interest

The authors have no competing interests.

Supplementary material

40203_2018_47_MOESM1_ESM.docx (29 kb)
Supplementary material 1 (DOCX 28 kb)

References

  1. Ahmad A, Ahad A, Rao AQ, Husnain T (2015) Molecular docking based screening of neem-derived compounds with the NS1 protein of Influenza virus. Bioinformation 11:359CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bonifácio BV, da Silva PB, dos Santos Ramos MA, Negri KMS, Bauab TM, Chorilli M (2014) Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomed 9:1CrossRefGoogle Scholar
  3. Byler KG, Ogungbe IV, Setzer WN (2016) In-silico screening for anti-Zika virus phytochemicals. J Mol Graph Model 69:78–91CrossRefPubMedGoogle Scholar
  4. Chemin I, Zoulim F (2009) Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 286:52–59CrossRefPubMedGoogle Scholar
  5. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771–4779CrossRefPubMedPubMedCentralGoogle Scholar
  6. Dibyajyoti S, Bin ET, Swati P (2013) Bioinformatics: the effects on the cost of drug discovery. Galle Med J 18:44–50CrossRefGoogle Scholar
  7. Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350:1118–1129CrossRefPubMedGoogle Scholar
  8. Jain J, Kumari A, Somvanshi P, Grover A, Pai S, Sunil S (2017) In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus. F1000Research 6:1601CrossRefPubMedPubMedCentralGoogle Scholar
  9. Jones SA, Clark DN, Cao F, Tavis JE, Hu J (2014) Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming. J Virol 88:1564–1572CrossRefPubMedPubMedCentralGoogle Scholar
  10. Kandagalla S, Sharath B, Bharath BR, Manjunatha H (2016) Molecular docking analysis of curcumin analogues against kinase domain of ALK5. In Silico Pharmacol 5:15CrossRefGoogle Scholar
  11. Khan MTH, Ather A, Thompson KD, Gambari R (2005) Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res 67:107–119CrossRefPubMedGoogle Scholar
  12. Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH (2001) Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res 15:718–720CrossRefPubMedGoogle Scholar
  13. Kim K-H, Kim ND, Seong B-L (2010) Discovery and development of anti-HBV agents and their resistance. Molecules 15:5878–5908CrossRefPubMedGoogle Scholar
  14. Kurokawa M et al (1999) Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica In vitro and in vivo. J Pharmacol Exp Ther 289:72–78PubMedGoogle Scholar
  15. Langley DR et al (2007) Inhibition of hepatitis B virus polymerase by entecavir. J Virol 81(8):3992–4001CrossRefPubMedPubMedCentralGoogle Scholar
  16. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11:97–107CrossRefGoogle Scholar
  17. Lin X, Zhang S, Huang Q, Zheng L, Huang J, Zhang X, Huang R (2013) Anti-hepatitis B virus activity of total saponins isolated from Taraphochlamys affinis in vitro and in vivo. J Med Plants Res 7:2841–2846Google Scholar
  18. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update. Hepatology 50:661–662CrossRefPubMedGoogle Scholar
  19. Lu F, Zhuang H (2009) Management of hepatitis B in China. Chin Med J (Engl) 122:3–4Google Scholar
  20. Mak L-Y, Seto W-K, Lai C-L, Yuen M-F (2016) DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. Expert Opin Drug Saf 15:383–392CrossRefPubMedGoogle Scholar
  21. Mekha Mohan PJ, Valsalan R, Nazeem PA (2015) Molecular docking studies of phytochemicals from Phyllanthus niruri against hepatitis B DNA polymerase. Bioinformation 11:426CrossRefPubMedPubMedCentralGoogle Scholar
  22. Meng F-C, Xu W-R, Li Y-Z, Huang Z-M, Liang G-Y, Liu C-X (2015) In silico molecular docking study of repensine and bentysrepinine against HBV DNA polymerase. Chin Herb Med 7:39–44CrossRefGoogle Scholar
  23. Michel M-L, Deng Q, Mancini-Bourgine M (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54(6):1286–1296CrossRefPubMedGoogle Scholar
  24. Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, Parveen Z (2008) Antiviral potentials of medicinal plants. Virus Res 131:111–120CrossRefPubMedGoogle Scholar
  25. Muzaffer U, Paul V, Prasad NR (2016) Molecular docking of selected phytoconstituents with signaling molecules of ultraviolet-B induced oxidative damage. In Silico Pharmacol 5:17CrossRefGoogle Scholar
  26. Nassal M, Schaller H (1993) Hepatitis B virus replication. Trends Microbiol 1:221–228CrossRefPubMedGoogle Scholar
  27. Neuveut C, Wei Y, Buendia MA (2010) Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52:594–604CrossRefPubMedGoogle Scholar
  28. Noordeen F (2015) Hepatitis B virus infection: an insight into infection outcomes and recent treatment options. Virusdisease 26:1–8CrossRefPubMedPubMedCentralGoogle Scholar
  29. Shaw T, Mok SS, Locarnini SA (1996) Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24:996–1002CrossRefPubMedGoogle Scholar
  30. Shin MS, Kang EH, Lee YI (2005) A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res 67:163–168CrossRefPubMedGoogle Scholar
  31. Siddiqui MH, Alamri SA, Al-Whaibi MH, Hussain Z, Ali HM, El-Zaidy ME (2017) A mini-review of anti-hepatitis B virus activity of medicinal plants. Biotechnol Biotechnol Equip 31:9–15CrossRefGoogle Scholar
  32. Soltan MM, Zaki AK (2009) Antiviral screening of forty-two Egyptian medicinal plants. J Ethnopharmacol 126:102–107CrossRefPubMedGoogle Scholar
  33. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2:16CrossRefPubMedPubMedCentralGoogle Scholar
  34. Utsunomiya T, Kobayashi M, Herndon DN, Pollard RB, Suzuki F (1995) Glycyrrhizin (20β-carboxy-11-oxo-30-norolean-12-en-3β-yl-2-O-β-d-glucopyranuronosyl-α-d-glucopyranosiduronic acid) improves the resistance of thermally injured mice to opportunistic infection of herpes simplex virus type 1. Immunol Lett 44:59–66CrossRefPubMedGoogle Scholar
  35. Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K (2014) A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int 2014:186864.  https://doi.org/10.1155/2014/186864 CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Mokhtar Nosrati
    • 1
  • Zahra Shakeran
    • 1
  • Zainab Shakeran
    • 2
  1. 1.Department of Biotechnology, Faculty of Advanced Science and TechnologiesUniversity of IsfahanIsfahanIran
  2. 2.Department of Biology, Faculty of ScienceUniversity of IsfahanIsfahanIran

Personalised recommendations